CN1253201C - 一种治疗偏头痛的药物 - Google Patents
一种治疗偏头痛的药物 Download PDFInfo
- Publication number
- CN1253201C CN1253201C CN 00110854 CN00110854A CN1253201C CN 1253201 C CN1253201 C CN 1253201C CN 00110854 CN00110854 CN 00110854 CN 00110854 A CN00110854 A CN 00110854A CN 1253201 C CN1253201 C CN 1253201C
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- weight proportion
- raw material
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 206010019233 Headaches Diseases 0.000 title description 21
- 229940079593 drug Drugs 0.000 title description 10
- 241001643642 Viticis Species 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims description 10
- 241000628997 Flos Species 0.000 claims description 8
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 241000756943 Codonopsis Species 0.000 claims description 2
- 239000009670 cang er zi wan Substances 0.000 claims description 2
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 30
- 208000019695 Migraine disease Diseases 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 208000002193 Pain Diseases 0.000 abstract description 9
- 206010027599 migraine Diseases 0.000 abstract description 9
- 230000036407 pain Effects 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241001254604 Angelica pubescens Species 0.000 abstract 1
- 235000014429 Angelica sylvestris Nutrition 0.000 abstract 1
- 241000758794 Asarum Species 0.000 abstract 1
- 235000007516 Chrysanthemum Nutrition 0.000 abstract 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 241000510667 Conioselinum Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 240000004370 Pastinaca sativa Species 0.000 abstract 1
- 235000017769 Pastinaca sativa subsp sativa Nutrition 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 241000207929 Scutellaria Species 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 235000006886 Zingiber officinale Nutrition 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 235000008397 ginger Nutrition 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 description 20
- 230000006870 function Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 230000002048 spasmolytic effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000001140 Night Blindness Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 2
- 229960004943 ergotamine Drugs 0.000 description 2
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- WMBOCUXXNSOQHM-FLIBITNWSA-N (Z)-3-butylidenephthalide Chemical compound C1=CC=C2C(=C/CCC)/OC(=O)C2=C1 WMBOCUXXNSOQHM-FLIBITNWSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 201000009487 Amblyopia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 241000212948 Cnidium Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- -1 Coumarins chemical compound Chemical class 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 101710106745 Histamine oxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007316 Neurocysticercosis Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229940118377 Vitamin antagonist Drugs 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- WMBOCUXXNSOQHM-UHFFFAOYSA-N n-butylidenephthalide Natural products C1=CC=C2C(=CCCC)OC(=O)C2=C1 WMBOCUXXNSOQHM-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于一种治疗偏头痛的药物,它主要由当归、川芎、白芷、羌活、独活、苍术、防风、麦冬、黄芩、蔓荆子、菊花、细辛、甘草、生姜制作而成,为纯中药制剂,服用方便,具有祛风散寒、清热除湿、活血蠲痛、补气血、柔肝止痛的功效,对治疗偏头痛效果较好,治愈率达65%,有效率达98%。
Description
本发明属于一种内服用中草药,特别是一种用于治疗偏头痛的药物。
头痛是一个自觉症状,是颅内外因素对痛觉敏感结构受到刺激而引起的一种临床上极为常见的病症,常见的因素为炎症、颅部外伤、脑血管病变、颅内肿瘤、脑囊虫病、N系统功能障碍、五官科疾病等,上述因素可使颅内脑膜、动脉、静脉和颅外动脉、三叉神经、舌咽神经、迷走神经、劲1—3神经受刺激,造成血管扩和、痉孪,移痊或受牵拉,而产生头痛。其发病率女性高于男性。结合国内外资料显示,女性病发率为12.9—17.6%。;男性为3.4—6.1%,因此发病率较高,给患者造成精神和肉体上的极大痛苦,是一种较为顽固的病症。
目前西医一般采用前列腺抑制剂或血管收缩剂药物治疗,如阿司匹林、消炎痛、或麦角胺、双氢麦秀胺等,由于麦角类等药物对人体有一定的副作用,且有成隐性,对人体造成一定的伤害。同时只能临时缓解头痛症状,达不到根治的目的。
中医上一般采用针灸、推拿、外贴和内服药物的辩证施治,有一定的疗效。但疗效较差,治愈率低。
本发明的目的在于提供一种可有效治疗偏头痛的药物,内服使用、治愈率较高。
本发明是这样实现的:
一种治疗偏头痛的药物,其特征在于它是由下述重量配比的原料制作而成的药剂:当归3--5,川芎3--5,白芷3--5,羌活3--5,独活3--5,苍术3--5,防风3--5,麦冬3--5,黄芩4--6,蔓荆子2--4,菊花2--4,细辛1--3,甘草1--3,生姜1--2。
本发明为纯中药制作,现代药理研究证明:
当归,含挥发油约,成份为正丁叉苯酞,具当归固有之香气,并含有正—酰苯邻羧酸、谷甾醇,维生素B12,维生素E,烟酸,蔗糖。具有兴奋子宫肌、使收缩加强的作用,实验证明对子宫作用具有双向性。有抗维生素E缺乏症之作用。能降低心肌的兴奋性。对实验性能动脉粥样硬化有一定疗效。
川芎,含挥发油,油内成份是川芎内脂、川芎酸、川芎酸酯和醇性物,用于局部有刺激作用,对于延髓血管运动中枢、呼吸中枢等亢奋作用,对大脑则麻痹。
白芷,含香豆精类化合物,有扩张动脉作用,小量能兴奋神经中枢,能增强呼吸、使血压上升。大量能引起间歇性惊厥。
羌活,含挥发油,对布鲁氏杆菌有抑制作用。
独活,含天冬酰胺等,有镇痛、镇痉、催眠作用,并有扩张血管,降低血压的作用。
苍术,主要成份为苍术醇,对夜盲症、软骨病、皮肤角化症有效,有降血糖作用。
防风,含挥发油及甘露醇、酚类物质,多糖类及有机酸,主要有解热作用。
麦冬,含多种甾体皂甙,对白色葡萄球菌、枯草杆菌、大肠杆菌及伤寒杆菌有抑制作用。
黄芩,含有五种黄酮成份,其煎剂对甲型链球菌、肺炎球菌等有抑制作用。对实验性发热有解热作用。还有降压、利尿、利胆、保肝、升高血糖等作用。
蔓荆子,含紫花牡菊素、生物碱,有镇痛作用,用于神经性头痛、肌肉痛,并有调节体温中枢退热作用,对肝肾虚损的夜盲及弱视有一定疗效。
菊花,含菊花苷、维生素B1、挥发油等,有解热作用,水煎剂可治疗冠心病,也可用于治疗急性结合膜炎、高血压等病。
细辛,含精油,其中有少量细辛铜,有发汗、镇痛及麻醉作用,并有祛痰湿作用。临床上对头痛、腰痛、身痛、牙痛有一定疗效。
甘草,含甘草甜素,有较强的解毒作用,对平滑肌痉孪有缓解作用,具有抗炎及抗变态反应的作用。
生姜,用于增强上述诸药的联合药效。
本发明药物为纯中药制作而成,具有祛风散寒、清热除湿、活血蠲痛、补气血、柔肝止痛的功效,对治疗偏头痛效果较好,治愈率达65%,有效率达98%。其综合作用为:
1、中医理论认为,头为清阳之府、诸阳之会,五脏六腑的病变都上汇于头部,固本发明药物具有疏散风邪、平衡阴阳、和畅清阳、平肝熄风、活血化瘀、补血活血、行气、温通经络、除烦安神、安脑止痛等作用。
2、西医理论认为,本发明药物配比科学,还可作用于中枢神经系统。具有镇痉、解痉、镇痛、镇静的作用,因而可改善微循环。有调节动脉血管缩张作用。即对动脉血管有明显的松驰作用,并可降低血管阻力,增加脑血流量,降低血液粘度,以改变因供血不足而引起的缺血缺氧造成的头痛症状。
3、抑制血小板的聚集的作用。偏头痛病人血小板中含有较多的ADP和ATP与钙,还含有腺嘌呤等物质,且偏头痛病人血小板单胺氧化酶活性降低。本配方可直接对此病理现象进行调节,使其恢复到生理范围内。
4、免疫调节作用。偏头痛病人血中抗原抗体免疫复合物高于正常人3倍,这种复合物可触发组织的损害,从而释放多种血管活性物质,如组织胺及5—HT等。因而调节偏头痛症人的免疫能力是十分必要的。因本发明配方中含补血活血、益气健脾类药物,使本配方具有此项功能。
5、参与碳水化合物及自由脂肪酸的代谢作用,偏头痛发作时,糖耐量降低,血浆胰岛素水平降低,血浆自由脂肪酸、甘油、酮体及生长素水平升高,故祛风除湿药物的参与可直接对此进行调节。另外对前列腺素、儿茶酚胺、神经肽、组织胺及单胺氧化酶的变化也起一定的调节作用。
本发明药物临床使用结果表明,具有下述优点:
1、本发明选用天然植物为原料,各组分含量配比科学,利用各味中药的综合作用,可有效治疗各种原因所致的偏头痛,无毒副作用,成本低,服用方便。
2、本发明以强身固本为出发点,辅以祛风散寒、活血祛於、扶正去邪、平衡阴阳之作用,标本兼治。
3、本发明药物可单独主方使用,也可根据不同原因、不同部位的发病配以附方,治疗效果更明显。
4、本发明配方药量极轻,用药短小精焊,以轻清取效,避免了以往药量过重、容易损伤胃气的副作用。讲究选药精严,小方精药,力挽沉疴。
5、本发明对一切新旧、远近头痛均有效,疗程短,治愈率高。
下面结合实施例对本发明作进一步说明。
实施例1,取当归5克,川芎5克,白芷5克,羌活5克,独活5克,苍术5克,防风5克,麦冬5克,黄芩6克,蔓荆子4克,菊花4克,细辛3克,甘草3克,生姜2克,用水煎服,每天一次,12天为一疗程,可有效治疗各种原因所致的偏头痛。
实施例2,取上述重量配比的中药,再加入柴胡、生地各4克,红花、龙胆草各5克,服用方法与上同,可有效治疗左侧偏头痛。
实施例3,取上述重量配比的中药,再加入黄芪、葛根各3克,可有效治疗右侧偏头痛。
实施例4,取上述重量配比的中药,再加入天麻2克,山楂、枳实、半夏各4克,可有效治疗前额眉棱骨痛。
实施例5,取上述重量配比的中药,再加入藁本、大黄各3克,可有效治疗癫顶痛。
实施例6,取上述重量配比的中药,再加入苍耳子5克,木瓜、荆芥各3克,可有效治疗风入脑髓所致头痛。
实施例7,取上述重量配比的中药,再加入黄芪6克、党参6克、白芍3克、生地4克,可有效气血二虚,常有自汗类头痛。
为验证本发明药物的效果,从96至今在山东省阳谷县冀承环诊所进行了如下临床试验,共试验头痛患者病人180例,年龄12—70岁之间,病史0。3—32年不等。随机分为二组,其中一组服用本发明药物,为试验组,共95例;一组服用麦角胺及水杨酸类药物,为对照组,共85例。12天为一疗程。
疗效标准为:1、自感头痛症状消失、脑电图、脑血液图检查属正常范围者为治愈;2、自感头痛症状减轻、但仍偶尔发作者,及脑电图、脑血液图检查仍为异常但较治疗前有改善者为有效;3、用药后,痛疼症状无缓解或加重者为无效。
疗效报告如下:
1、试验组中,有效92例、治愈80例,随访1—2年无复发;无效3例。
2、对照组中,有效48例、治愈17例,随访1—2年无复发;无效20例。
从上述试验组中,随机抽取5人,具体为:
例1,46岁,女,97年初诊,主诉自85年起感觉左侧头痛,血压达170/90mmHG,服用过降压药,但血压下降后,头痛加重,并伴有耳鸣。诊断为血症所致头痛,服用本发明药物,用药1周,完全治愈。随访2年未复发。
例2,男,40岁,98年初诊。10余年前开始发生头痛,其后加重,每月发作2—3次,有时持续数天,诊断为前额及双侧太阳穴型头痛。服用本发明药物6次,症状消失。随访一年未复发。
例3、男,58岁,98年初诊,头痛15年。服用本发明药物13次,症状减轻,继续服用5剂后,完全治愈,随访无复发。
例4、女,38岁,头痛6个余月,表现时重时轻,疼痛部位不固定,曾服用多种药物无效,近来加重。服用本发明药物12剂,疼痛消失。
例5、女,16岁,99年初诊,自述陈发性头痛2年余,服用本发明药物8剂,症状消除,随访无复发。
Claims (8)
1、一种治疗偏头痛的药物,其特征在于它是由下述重量配比的原料制作而成的药剂:
当归3--5,川芎3--5,白芷3--5,羌活3--5,独活3--5,苍术3--5,防风3--5,麦冬3--5,黄芩4--6,蔓荆子2--4,菊花2--4,细辛1--3,甘草1—3和生姜1--2。
2、根据权利要求1所述的治疗偏头痛的药物,其特征在于其中各原料的重量配比是:
当归5,川芎5,白芷5,羌活5,独活5,苍术5,防风5,麦冬5,黄芩6,蔓荆子4,菊花4,细辛3,甘草3和生姜2。
3、根据权利要求2所述的治疗偏头痛的药物,其特征在于它还含有下述重量配比的原料:柴胡4,生地4,红花5,龙胆草5。
4、根据权利要求2所述的治疗偏头痛的药物,其特征在于它还含有下述重量配比的原料:黄芪3,葛根3。
5、根据权利要求2所述的治疗偏头痛的药物,其特征在于它还含有下述重量配比的原料:天麻2,山楂4,枳实4,半夏4。
6、根据权利要求2所述的治疗偏头痛的药物,其特征在于它还含有下述重量配比的原料:藁本3,大黄3。
7、根据权利要求2所述的治疗偏头痛的药物,其特征在于它还含有下述重量配比的原料:苍耳子5,木瓜3,荆芥3。
8、根据权利要求2所述的治疗偏头痛的药物,其特征在于它还含有下述重量配比的原料:黄芪6,党参6,白芍3,生地4。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00110854 CN1253201C (zh) | 2000-01-27 | 2000-01-27 | 一种治疗偏头痛的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00110854 CN1253201C (zh) | 2000-01-27 | 2000-01-27 | 一种治疗偏头痛的药物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1270043A CN1270043A (zh) | 2000-10-18 |
| CN1253201C true CN1253201C (zh) | 2006-04-26 |
Family
ID=4580816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00110854 Expired - Fee Related CN1253201C (zh) | 2000-01-27 | 2000-01-27 | 一种治疗偏头痛的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1253201C (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101130055B (zh) * | 2007-09-18 | 2010-06-02 | 江苏济川制药有限公司 | 一种治疗头痛药物的生产方法 |
| CN101773651A (zh) * | 2010-04-19 | 2010-07-14 | 泰一和浦(北京)中医药研究院有限公司 | 一种治疗头痛的中药组合物及其制备方法 |
| CN102302751A (zh) * | 2011-08-19 | 2012-01-04 | 高朱荣 | 治疗偏头痛的中药 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100345567C (zh) * | 2006-01-17 | 2007-10-31 | 常效春 | 一种用于治疗功能性头痛的药物 |
| CN101095900B (zh) * | 2007-07-10 | 2010-11-10 | 黑龙江省中医研究院 | 川菊止痛胶囊及制备方法 |
| CN101167817B (zh) * | 2007-10-20 | 2011-12-07 | 刘衍 | 一种治疗偏头痛的中药 |
| CN102145132B (zh) * | 2011-03-13 | 2012-07-25 | 刘秀娥 | 一种治疗眉棱骨痛的中药 |
| CN102342994B (zh) * | 2011-10-18 | 2013-06-26 | 刘运波 | 一种治疗三叉神经痛的中药 |
| CN102641418B (zh) * | 2012-05-14 | 2013-09-25 | 文庆贤 | 一种治疗偏头痛的药剂 |
| CN102727834B (zh) * | 2012-07-18 | 2013-09-04 | 南京中医药大学 | 一种治疗偏头痛的中药组合物及其制备方法和应用 |
| CN103272126A (zh) * | 2013-05-30 | 2013-09-04 | 龙舟 | 一种治疗偏头痛的中药 |
| CN103263575B (zh) * | 2013-06-01 | 2015-01-14 | 周留侠 | 一种治疗头痛的药物及其制备方法 |
| CN103330786B (zh) * | 2013-07-11 | 2015-06-17 | 西华大学 | 一种治疗偏头痛的药物组合物及其制备方法和用途 |
| CN103385933B (zh) * | 2013-07-19 | 2014-11-05 | 苏州市天灵中药饮片有限公司 | 一种包含儿茶的中药及其制备方法 |
| CN103585596B (zh) * | 2013-10-18 | 2015-06-17 | 程广金 | 一种用于治偏头痛的中药组合物 |
| CN103611129A (zh) * | 2013-11-28 | 2014-03-05 | 秦雅昀 | 一种治疗神经性头痛的中药 |
| CN103816367B (zh) * | 2014-03-05 | 2016-03-23 | 刘瑞英 | 一种治疗偏头痛的中药 |
| CN103920020A (zh) * | 2014-04-15 | 2014-07-16 | 韩世昌 | 一种治疗头痛的中药组合物及其制备方法 |
| CN104383297A (zh) * | 2014-10-30 | 2015-03-04 | 蔡炜 | 一种治疗偏头痛的药物 |
| CN104435692A (zh) * | 2014-12-19 | 2015-03-25 | 徐杨来 | 治疗神经性头痛的方剂及其制备方法 |
| CN105233007A (zh) * | 2015-10-30 | 2016-01-13 | 王志勇 | 一种治疗偏头疼的中药组合物及其制备方法 |
| CN106511504A (zh) * | 2016-12-20 | 2017-03-22 | 刘震 | 一种调理偏头痛的中成药 |
| CN108420896A (zh) * | 2017-02-14 | 2018-08-21 | 吴金霞 | 祛风止痛化瘀汤 |
| CN107080787A (zh) * | 2017-04-28 | 2017-08-22 | 吴冬梅 | 镇静止痛散火汤 |
| CN108159349A (zh) * | 2018-01-17 | 2018-06-15 | 王芬 | 一种治疗偏头痛的中药制剂及其制备方法 |
| CN108096511A (zh) * | 2018-01-24 | 2018-06-01 | 刘清 | 一种快速缓解偏头痛的中药制剂及其制造方法 |
-
2000
- 2000-01-27 CN CN 00110854 patent/CN1253201C/zh not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101130055B (zh) * | 2007-09-18 | 2010-06-02 | 江苏济川制药有限公司 | 一种治疗头痛药物的生产方法 |
| CN101773651A (zh) * | 2010-04-19 | 2010-07-14 | 泰一和浦(北京)中医药研究院有限公司 | 一种治疗头痛的中药组合物及其制备方法 |
| CN102302751A (zh) * | 2011-08-19 | 2012-01-04 | 高朱荣 | 治疗偏头痛的中药 |
| CN102302751B (zh) * | 2011-08-19 | 2013-06-19 | 周正山 | 治疗偏头痛的中药 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1270043A (zh) | 2000-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1253201C (zh) | 一种治疗偏头痛的药物 | |
| CN103211990B (zh) | 一种治疗口腔溃疡的中药组合物 | |
| CN102247552A (zh) | 心脑血管葛根山药胶囊 | |
| CN106668508A (zh) | 一种治疗神经衰弱的中药方剂 | |
| CN100467055C (zh) | 治疗心律失常、冠心病、心绞痛的外用药 | |
| CN104667050B (zh) | 一种治疗失眠的中药 | |
| CN102293941B (zh) | 一种治疗糖尿病的中药组合物 | |
| CN101683443A (zh) | 一种化瘀强心中药组合物 | |
| CN106619988A (zh) | 一种治疗腰腿痛的中药泡脚及其制备方法 | |
| CN105617042A (zh) | 一种治疗头痛的中药组合物 | |
| CN119700869B (zh) | 一种治疗腹泻型脾肾阳虚证ibs的中药组合物、中药颗粒剂 | |
| CN101961459B (zh) | 一种治疗偏枯的内服药物 | |
| CN103861067A (zh) | 一种治疗鼻窦炎的中药混合物 | |
| CN101444616B (zh) | 一种治疗慢性风湿病痛的药酒及其制备方法 | |
| CN103083613A (zh) | 一种治疗偏头痛的中药组合物 | |
| CN101954018A (zh) | 一种治疗慢性肾炎的内服药物 | |
| CN101181614B (zh) | 一种治疗脑血管病所致肢体麻木的药物 | |
| CN1299748C (zh) | 一种减肥调理补气袋 | |
| CN101045145A (zh) | 一种改善性功能的保健品 | |
| CN101912547B (zh) | 一种治疗眩晕的药物及其制备方法 | |
| CN105998559A (zh) | 治疗帕金森病的中药组合物 | |
| CN1739782A (zh) | 外用刮痧拔罐保健治病药酒 | |
| CN110464803A (zh) | 一种用于降低血压的中药组合物及其制备方法 | |
| CN105833074A (zh) | 治疗口腔溃疡的中药组合物 | |
| CN105169324A (zh) | 防治风寒感冒的中药制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |